Biosimilars – Forecast – Oncology
In 2024, sales of branded MAb biologics in oncology exceeded $48 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled $5.9 billion. Throughout the 2024-2034 forecast period, increasing numbers of branded biologics will lose patent protection, and biosimilars will enter the market and erode patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Table of contents
- Biosimilars - Forecast - Oncology
- Oncology MAb Forecasts
- G-CSF Forecasts
- Key takeaways
- Overview
- Drug-Specific Forecast Assumptions
Related Market Assessment Reports
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Atopic Dermatitis (Pediatric) (US)
Atopic dermatitis (AD) is a chronic, itchy, inflammatory skin disease often starting in childhood. It is usually treated with topical immunotherapy. Refractory cases may need systemic…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Unmet Need – Unmet Need – Unresectable Locally Advanced or Metastatic Bladder Cancer (US/EU)
The unresectable locally advanced or metastatic bladder cancer treatment landscape continues to evolve, driven by the integration of immunotherapy, targeted agents, and antibody–drug conjugates (…
